NNI 351
Alternative Names: NNI-351Latest Information Update: 28 Oct 2024
At a glance
- Originator Neuronascent
- Class Anxiolytics; Behavioural disorder therapies; Small molecules
- Mechanism of Action DYRK kinase inhibitors; Nerve growth factor stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Attention-deficit hyperactivity disorder; Down syndrome; Fragile X syndrome; Post-traumatic stress disorders
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for preclinical development in Attention-deficit-hyperactivity-disorder in USA (PO)
- 28 Oct 2024 No recent reports of development identified for preclinical development in Fragile-X-syndrome in USA (PO)
- 28 Sep 2022 No recent reports of development identified for preclinical development in Down syndrome in USA (PO)